TNFRSF4 and hepatocellular carcinoma: Overall, agonists targeting co-stimulatory immune checkpoint receptors such as CD40 and OX40 have demonstrated potential for enhancing the antitumor immune response in HCC, either alone or together with other immunotherapeutic agents.